Back to Journals » OncoTargets and Therapy » Volume 11

Peripheral blood lymphocyte responses to cytomegalovirus seropositivity after allogeneic-hematopoietic stem cell transplantation

Authors Zhang J, Chen X, Rong G, Xu T, Zhao H, Chen D, Wu L, Huang P, Wang F

Received 18 December 2017

Accepted for publication 3 May 2018

Published 24 August 2018 Volume 2018:11 Pages 5143—5150

DOI https://doi.org/10.2147/OTT.S160178

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Justinn Cochran

Peer reviewer comments 2

Editor who approved publication: Professor Jianmin Xu


Jiexin Zhang,1,2,* Xian Chen,1,2,* Guodong Rong,1,2 Ting Xu,1,2 Hong Zhao,1,2 Dan Chen,1,2 Lei Wu,1,2 Peijun Huang,1,2 Fang Wang1,2

1Department of Laboratory Medicine, The First Affiliated Hospital of Nanjing Medical University, 210029, Nanjing, China; 2National Key Clinical Department of Laboratory Medicine, 210029, Nanjing, China

*These authors contributed equally to this work

Background: The main purpose of this study was to investigate the relationship among cytomegalovirus (CMV) viremia, peripheral immune cells alternations, and leukemia prognosis.
Patients and methods: We studied 90 leukemia patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT) from 2008 to 2015. Their complete clinical laboratory data were collected until 1 year after transplantation.
Results: All patients were serum CMV negative before allo-HSCT. After transplantation, the CMV reactivation group showed increased peripheral CD8+ T cells and decreased CD4+ T cells and B cells. However, CD8/CD4 ratio and B cells restored by control of CMV infection due to 2 months maximum course of ganciclovir treatment. CMV seropositivity was positively related to leukemia-free survival (LFS) of all recruited leukemia types.
Conclusion: In summary, CMV drives immune cell post-transplantation fluctuation, which also favors LFS of leukemia partly resulted from CD8+ T cells.

Keywords: cytomegalovirus, leukemia, allo-HSCT, CD8+ T cells, leukemia-free survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]